BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:With Biogen investing millions in Ionis' efforts to weaponize 
 ASOs against SMA\, Stoke Therapeutics collaborating with Acadia Pharmaceu
 ticals to supercharge the development of RNA-Based treatments for genetic
  neurodevelopmental diseases and the global oligonucleotide therapeutics 
 market set to experience unprecedented growth\, there’s never been a more
  opportune moment for biopharma to expand their oligonucleotide pipelines
  into the untapped potential of the CNS.\n\nDedicated to providing you wi
 th the insights you need to create clinically defining oligonucleotide th
 erapeutics\, the 2nd Oligonucleotides for CNS Summit will unite a multina
 tional faculty of experts from Eli Lilly\, Roche\, Biogen\, Alnylam\, Ser
 vier\, Stoke Therapeutics and more to divulge the critical insights you n
 eed to accelerate your oligonucleotide therapeutic development against Al
 zheimer’s\, Huntington’s\, Glioblastoma and more!\n\nFrom learning how to
  manipulate oligonucleotide chemistry to maximize therapeutic potency to 
 more effectively collaborating with CROs/CMOs to manufacture therapies in
  line with regulatory standards and exploring antibodies\, small Molecule
 s &amp\; nanoparticles for movement across the blood brain barrier\, this
  focused industry forum will give you the chance to gain back-to-back ins
 ights on the science propelling oligonucleotide therapeutics forward in 2
 022.\n\nAs industry turn their heads towards the CNS in a bid to capitali
 ze on its strategic opportunity\,  join 150+ ASO and RNA-Based therapeuti
 c experts this June at this unique forum for a dynamic mix of formal pres
 entations\, audience discussions\, panel discussions and organized networ
 king and leave with the expertise your team needs to optimize your oligon
 ucleotides approach in the CNS this year.\n
DTEND:20220615T151500
DTSTAMP:20260512T214259Z
DTSTART:20220613T070000
LOCATION:Hilton Boston Logan Airport\, One Hotel Drive\, Boston\, Massachu
 setts\, 02128\,
SEQUENCE:0
SUMMARY:With Biogen investing millions in Ionis' efforts to weaponize ASOs
  against SMA\, Stoke Therapeutics collaborating with Acadia Pharmaceutica
 ls to sup...
UID:bf2ecc50-b64e-4bed-9296-310f1c0e425c
END:VEVENT
END:VCALENDAR